About

About PEPTOMYC SL Peptomyc is a Barcelona-based spin-off from the Vall d'Hebron Institute of Oncology aiming at revolutionising cancer treatment with anti-MYC mini-proteins. Clinical-stage biotech developing the first and only clinical-stage direct inhibitor of MYC for cancer, with a pipeline in targeting other undruggable transcription factors. OMO-103: First-in-Class cell-penetrating mini-protein MYC inhibitor: -Excellent safety & PK profile in patients -Demonstrated disease stabilization & tumor size reduction (best response 49%) in advanced solid tumor patients in monotherapy -Dose-dependent target engagement -Identified predictive biomarkers of response -PDAC and NSCLC as primary indications, potential in other cancers & breakthrough designations Promising pipeline of targeted MYC degraders, mRNA delivery approaches and targeted antibody- and radioligand-mini-protein conjugates for oncology, immune- or ageing-related diseases Investment opportunity: €30M series C to fund OMO-103 Phase 1b/2a & pipeline expansion Partnering opportunity: Looking for licensing partners for Greater China & Asia. Strong potential for combination therapies (standard & targeted therapies) About Peptomyc Peptomyc is a Barcelona-based spin-off from the Vall d'Hebron Institute of Oncology aiming at revolutionising cancer treatment with anti-MYC mini-proteins. Clinical-stage biotech developing the first and only clinical-stage direct inhibitor of MYC for cancer, with a pipeline in targeting other undruggable transcription factors. OMO-103: First-in-Class cell-penetrating mini-protein MYC inhibitor: -Excellent safety & PK profile in patients -Demonstrated disease stabilization & tumor size reduction (best response 49%) in advanced solid tumor patients in monotherapy -Dose-dependent target engagement -Identified predictive biomarkers of response -PDAC and NSCLC as primary indications, potential in other cancers & breakthrough designations Promising pipeline of targeted MYC degraders, mRNA delivery approaches and targeted antibody- and radioligand-mini-protein conjugates for oncology, immune- or ageing-related diseases Investment opportunity: €30M series C to fund OMO-103 Phase 1b/2a & pipeline expansion Partnering opportunity: Looking for licensing partners for Greater China & Asia. Strong potential for combination therapies (standard & targeted therapies) Peptomyc is a clinical stage company focused on the development of a new generation of cell penetrating proteins (CPPs) targeting MYC, the most dysregulated oncogene in human cancer. MYC holds a non-redundant function in at least 70% of human cancers, hence targeting MYC is the most promising therapeutic opportunity to date. Despite that, there is currently no MYC inhibitor in the market. Our lead compound, OMO-103, is the first MYC inhibitor to have successfully completed a Phase I clinical trial in all-comers solid tumours and is now being tested in a Phase Ib combination study with SOC chemotherapy in mPDAC, and in a Phase 2 study in monotherapy in advanced osteosarcoma. Combinations with KRASi and PARPi are being explored as well. Peptomyc is now expanding its pipeline to include radioligands and miniprotein therapeutics for brain tumors and brain metastases, among others. Our series C round of investment is currently open.